“MIATA”—Minimal Information about T Cell Assays

Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of...

Full description

Saved in:
Bibliographic Details
Published in:Immunity (Cambridge, Mass.) Mass.), 2009-10, Vol.31 (4), p.527-528
Main Authors: Janetzki, Sylvia, Britten, Cedrik M., Kalos, Michael, Levitsky, Hyam I., Maecker, Holden T., Melief, Cornelius J.M., Old, Lloyd J., Romero, Pedro, Hoos, Axel, Davis, Mark M.
Format: Article
Language:English
Subjects:
Cancer Vaccines - immunology
Cancer Vaccines - therapeutic use
Clinical trials
Gene expression
Humans
Immunoassay
Immunoassay - standards
Immunotherapy
Laboratories
Lymphocytes
Meetings
Monitoring, Immunologic - standards
Neoplasms - therapy
Peptides
Practice Guidelines as Topic - standards
Quality standards
Reporting requirements
Stock rights
T-Lymphocytes - immunology
Viral Vaccines - immunology
Viral Vaccines - therapeutic use
Virus Diseases - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.
ISSN:1074-7613
1097-4180
DOI:10.1016/j.immuni.2009.09.007